Report Feature
The future of the global biopharmaceutical CMO (Contract Manufacturing Organization) & CRO (Contract Research Organization) market looks promising with opportunities in the pharmaceutical, biotechnological, and medical device industries. The global biopharmaceutical CMO & CRO market is expected to grow with a CAGR of 7%-9% from 2020 to 2025. The major drivers for this market are increasing demand for biologics, rising biopharmaceutical industry, and time and cost saving benefits offered to biopharmaceutical companies by contract services.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biopharmaceutical CMO & CRO market report, please download the report brochure.
In this market, biologics is the largest product type of biopharmaceutical CMO & CRO, whereas mammalian is the largest source. Growth in various segments of the biopharmaceutical CMO & CRO market are given below:
The study includes trends and forecast for the global biopharmaceutical CMO & CRO market by product, service, source, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
-
Biologics
- Monoclonal Antibodies (MAbs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi (Ribonucleic Acid Interference), & Molecular Therapy
- Others
- Biosimilars
By Service [Value ($ Million) shipment analysis for 2014 – 2025]:
-
Contract Manufacturing
-
Process Development
- Downstream
- Upstream
- Fill & Finish Operations
- Analytical & QC (Quality Control) Studies
- Packaging
-
Process Development
-
Contract Research
- Oncology
- Inflammation & Immunology
- Cardiology
- Neuroscience
- Others
By Source [Value ($ Million) shipment analysis for 2014 – 2025]:
- Mammalian
- Non-Mammalian
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
-
North America
- United States
- Canada
- Mexico
-
Europe
- United Kingdom
- Spain
- Germany
- France
-
Asia Pacific
- China
- India
- Japan
-
The Rest of the World
- Brazil
Some of the biopharmaceutical CMO & CRO companies profiled in this report include Lonza, Rentschler Biotechnologie, Boehringer Ingelheim, JRS Pharma, Inno Biologics, ProBioGen, Fujifilm Diosynth Biotechnologies, Samsung BioLogics, and Toyobo.
Lucintel forecasts that biologics will remain the largest product segment over the forecast period due to complex manufacturing steps, high specificity of biologics, and a higher success rate than other drug molecules.
Within this market, mammalian will remain the largest segment by source over the forecast period due to their capabilities of adding human-like post-translational modifications to complex protein therapeutics and new developments in this segment, leading to more productive and efficient manufacturing of biologics using mammalian cells.
North America will remain the largest region over the forecast period due to the presence of a large number of small and mid-size biopharmaceutical entities (SMEs) that are lacking the resources and budget to establish facilities with well-equipped resources in the region.
|
Features of the Global Biopharmaceutical CMO & CRO Market |
|
|
This report answers following key questions |
|
Q.1 What are some of the most promising potential, high-growth opportunities for the global biopharmaceutical CMO & CRO market by product (biologics (monoclonal antibodies (MAbs), recombinant proteins, vaccines, antisense, RNAi, & molecular therapy, and others) and biosimilars), service (contract manufacturing (process development (downstream and upstream), fill & finish operations, analytical & QC studies, and packaging) and contract research (oncology, inflammation & immunology, cardiology, neuroscience, and others)), source (mammalian and non-mammalian), and region (North America, Europe, Asia Pacific, and Rest of the World)? Q.2 Which segments will grow at a faster pace and why? Q.3 Which region will grow at a faster pace and why? Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biopharmaceutical CMO & CRO market? Q.5 What are the business risks and threats to the global biopharmaceutical CMO & CRO market? Q.6 What are the emerging trends in this biopharmaceutical CMO & CRO market and the reasons behind them? Q.7 What are some changing demands of customers in this biopharmaceutical CMO & CRO market? Q.8 What are the new developments in this biopharmaceutical CMO & CRO market? Which companies are leading these developments? Q.9 Who are the major players in this biopharmaceutical CMO & CRO market? What strategic initiatives are being implemented by key players for business growth? Q.10 What are some of the competitive products and processes in this biopharmaceutical CMO & CRO market, and how big of a threat do they pose for loss of market share via material or product substitution? Q.11 What M&A activities did take place in the last five years in the global biopharmaceutical CMO & CRO market? |
Report Scope
| Key Features | Description |
| Base Year for Estimation | 2019 |
|
Trend Period (Actual Estimates) |
2014-2019 |
| Forecast Period | 2020-2025 |
| Pages | More than 150 |
| Market Representation / Units | Revenue in US $ Million |
| Report Coverage | Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling |
| Market Segments | Product (Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars), Service (Contract Manufacturing (Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)), Source (Mammalian and Non-Mammalian) |
Regional Scope |
North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil) |
| Customization | 10% Customization without Any Additional Cost |
Table of Contents
1. Executive Summary
7.2 Emerging Trends in the Global Biopharmaceutical CMO & CRO Market
4.1 Global Biopharmaceutical CMO & CRO Market by Region
4.2.1 Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.2.2 Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.2.3 Market by Source: Mammalian and Non-Mammalian
4.2.4 The United States Biopharmaceutical CMO & CRO Market
4.2.5 The Canadian Biopharmaceutical CMO & CRO Market
4.2.6 The Mexican Biopharmaceutical CMO & CRO Market
4.3.1 Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.3.2 Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.3.3 Market by Source: Mammalian and Non-Mammalian
4.3.4 The Biopharmaceutical CMO & CRO Market of United Kingdom
4.3.5 The Spanish Biopharmaceutical CMO & CRO Market
4.3.6 The German Biopharmaceutical CMO & CRO Market
4.3.7 The French Biopharmaceutical CMO & CRO Market
4.4.1 Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.4.2 Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.4.3 Market by Source: Mammalian and Non-Mammalian
4.4.4 The Chinese Biopharmaceutical CMO & CRO Market
4.4.5 The Indian Biopharmaceutical CMO & CRO Market
4.4.6 The Japanese Biopharmaceutical CMO & CRO Market
4.5.1 Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, and Others) and Biosimilars
4.5.2 Market by Service: Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC Studies, and Packaging) and Contract Research (Oncology, Inflammation & Immunology, Cardiology, Neuroscience, and Others)
4.5.3 Market by Source: Mammalian and Non-Mammalian
4.5.4 Brazilian Biopharmaceutical CMO & CRO Market
7.1.1 Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Product
7.1.2 Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Service
7.1.3 Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Source
7.1.4 Growth Opportunities for the Global Biopharmaceutical CMO & CRO Market by Region
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
